+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Treatment Syndromes Dementia Movement Disorders Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 82 Pages
  • January 2024
  • Region: Global
  • Fairfield Market Research
  • ID: 5924970
Description Jump to:
Leading Pharmaceutical Companies Aim to Address Rising Incidence of Cognitive Defects

The global market for the treatment of syndromes related to dementia and movement disorders has witnessed remarkable growth in recent years, as the number of individuals affected by these conditions continues to rise. Dementia, a broad category of mental illnesses, and movement disorders, including Parkinson's disease, have presented significant challenges for both patients and caregivers worldwide. According to recent data, approximately 80% of people with movement disorders such as Parkinson's ultimately develop cognitive defects, further emphasizing the need for effective treatments.

Key Market Dynamics:

The increasing aging population across the globe is a driving force behind the rising number of dementia cases. This surge in cases has prompted healthcare providers to explore a range of solutions, including home care services, adult day care services, psychological therapies, medication, and medical devices tailored for last-stage dementia patients. Palliative care units are also witnessing significant growth in response to the demands of patients and their families.

However, despite the collective efforts to ease the burden on those affected by dementia and movement disorders, several challenges persist. These challenges include a stringent regulatory framework, bureaucratic hurdles in the drug approval process, insufficient funding for research and development, and the ongoing struggle to find effective therapeutic management methods. It is noteworthy that most drugs designed to treat these conditions fail to pass Phase III testing, creating a daunting roadblock in the quest to find viable treatments.

Regional Analysis:

Geographically, the North America region is expected to maintain its dominance in the global market for the treatment of syndromes associated with dementia and movement disorders. This dominance is driven by the growing aging population and the increasing incidence of neurodegenerative diseases. Over the next six years, the Asia region is also projected to experience higher growth rates in this market, signaling the need for innovative solutions to meet the rising demand.

Key Market Players:

Major companies at the forefront of the global market for the treatment of dementia and movement disorders include Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Valeant Pharmaceutical International, and Pfizer, among others. These industry leaders are dedicated to developing innovative treatments to address the complex challenges presented by these debilitating conditions.

Segment Analysis:

The global market for the treatment of syndromes related to dementia and movement disorders is categorized based on the drugs used for treatment, including progressive dementia, movement disorders, and progressive dementia with certain other neurological abnormalities. These segments encompass drugs tailored for specific conditions, diseases-based therapeutics, and those designed to address associated neurological abnormalities.

As the global community grapples with the growing burden of dementia and movement disorders, the healthcare and pharmaceutical industries are committed to advancing research and delivering effective treatments that enhance the quality of life for affected individuals and their families.

By Drugs Used to Treatment Progressive Dementia

  • Diseases Based Therapeutics Under Progressive Dementia
  • Drugs for Progressive Dementia

By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities

  • Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
  • Drugs for Progressive Dementia

By Drugs Used to Treat Movement Disorder Syndrome

  • Diseases Based Therapeutics Under Movement Disorder Syndrome
  • Drugs for Movement Disorder Syndrome

By Region

  • North America
  • Europe
  • Asia


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Treatment Syndromes Dementia Movement Disorders Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031
3.1. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
3.1.1.2. Drugs for Progressive Dementia
3.2. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
3.2.1.2. Drugs for Progressive Dementia
3.3. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
3.3.1.2. Drugs for Movement Disorder Syndrome
3.4. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031
4.1. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
4.1.1.2. Drugs for Progressive Dementia
4.2. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
4.2.1.2. Drugs for Progressive Dementia
4.3. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
4.3.1.2. Drugs for Movement Disorder Syndrome
4.4. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
4.4.1.2. U.S. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
4.4.1.3. U.S. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
4.4.1.4. Canada Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
4.4.1.5. Canada Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
4.4.1.6. Canada Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031
5.1. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
5.1.1.2. Drugs for Progressive Dementia
5.2. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
5.2.1.2. Drugs for Progressive Dementia
5.3. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
5.3.1.2. Drugs for Movement Disorder Syndrome
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
5.4.1.2. Germany Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
5.4.1.3. Germany Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
5.4.1.4. U.K. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
5.4.1.5. U.K. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
5.4.1.6. U.K. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
5.4.1.7. France Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
5.4.1.8. France Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
5.4.1.9. France Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
5.4.1.10. Italy Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
5.4.1.11. Italy Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
5.4.1.12. Italy Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
5.4.1.13. Turkey Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
5.4.1.14. Turkey Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
5.4.1.15. Turkey Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
5.4.1.16. Russia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
5.4.1.17. Russia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
5.4.1.18. Russia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
5.4.1.19. Rest of Europe Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
5.4.1.20. Rest of Europe Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
5.4.1.21. Rest of Europe Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031
6.1. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
6.1.1.2. Drugs for Progressive Dementia
6.2. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
6.2.1.2. Drugs for Progressive Dementia
6.3. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
6.3.1.2. Drugs for Movement Disorder Syndrome
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
6.4.1.2. China Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
6.4.1.3. China Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
6.4.1.4. Japan Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
6.4.1.5. Japan Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
6.4.1.6. Japan Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
6.4.1.7. South Korea Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
6.4.1.8. South Korea Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
6.4.1.9. South Korea Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
6.4.1.10. India Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
6.4.1.11. India Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
6.4.1.12. India Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
6.4.1.13. Southeast Asia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
6.4.1.14. Southeast Asia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
6.4.1.15. Southeast Asia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031
7.1. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
7.1.1.2. Drugs for Progressive Dementia
7.2. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
7.2.1.2. Drugs for Progressive Dementia
7.3. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
7.3.1.2. Drugs for Movement Disorder Syndrome
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
7.4.1.2. Brazil Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
7.4.1.3. Brazil Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
7.4.1.4. Mexico Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
7.4.1.5. Mexico Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
7.4.1.6. Mexico Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
7.4.1.7. Argentina Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
7.4.1.8. Argentina Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
7.4.1.9. Argentina Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
7.4.1.10. Rest of Latin America Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
7.4.1.11. Rest of Latin America Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
7.4.1.12. Rest of Latin America Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031
8.1. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
8.1.1.2. Drugs for Progressive Dementia
8.2. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
8.2.1.2. Drugs for Progressive Dementia
8.3. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
8.3.1.2. Drugs for Movement Disorder Syndrome
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
8.4.1.2. GCC Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
8.4.1.3. GCC Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
8.4.1.4. South Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
8.4.1.5. South Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
8.4.1.6. South Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
8.4.1.7. Egypt Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
8.4.1.8. Egypt Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
8.4.1.9. Egypt Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
8.4.1.10. Nigeria Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
8.4.1.11. Nigeria Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
8.4.1.12. Nigeria Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By Drugs Used to Treat Movement Disorder Syndrome vs By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities Heat map
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. F. Hoffmann-La Roche, Ltd.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Baxter
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Novartis AG
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Merck & Co., Inc.
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Sanofi
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Pfizer, Inc.
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Valeant Pharmaceuticals International, Inc.
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. AstraZeneca GmbH
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Abbott Laboratories, Inc.
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Bristol-Myers Squibb Company
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • F. Hoffmann-La Roche, Ltd.
  • Novartis AG.
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Valeant Pharmaceutical International, Inc.
  • AstraZeneca GmbH and Pfizer, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Dementia and Movement Disorder Treatment Market 2024-2028 - Product Image

Dementia and Movement Disorder Treatment Market 2024-2028

  • Report
  • 177 Pages
  • Global
From
Neurodegeneration. The Molecular Pathology of Dementia and Movement Disorders. Edition No. 2. International Society of Neuropathology Series - Product Image

Neurodegeneration. The Molecular Pathology of Dementia and Movement Disorders. Edition No. 2. International Society of Neuropathology Series

  • Book
  • 496 Pages
  • Global
The Neurobiology of the Gilles De La Tourette Syndrome and Chronic Tics: Part B. International Review of Movement Disorders Volume 4 - Product Image

The Neurobiology of the Gilles De La Tourette Syndrome and Chronic Tics: Part B. International Review of Movement Disorders Volume 4

  • Book
  • Global
The Neurobiology of the Gilles De La Tourette Syndrome and Chronic Tics: Part A. International Review of Movement Disorders Volume 3 - Product Image

The Neurobiology of the Gilles De La Tourette Syndrome and Chronic Tics: Part A. International Review of Movement Disorders Volume 3

  • Book
  • Global
Pathy's Principles and Practice of Geriatric Medicine. Edition No. 6 - Product Image

Pathy's Principles and Practice of Geriatric Medicine. Edition No. 6

  • Book
  • 1856 Pages
Copyright © 2002-2024 Research and Markets. All Rights Reserved.